- Home
- XPER vs CMRX Comparison
XPER vs CMRX Comparison
Compare XPER & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- CMRX
- Stock Information
- Founded
- XPER 1990
- CMRX 2000
- Country
- XPER United States
- CMRX United States
- Employees
- XPER N/A
- CMRX 81
- Industry
- XPER Semiconductors
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- XPER Technology
- CMRX Health Care
- Exchange
- XPER Nasdaq
- CMRX Nasdaq
- Market Cap
- XPER 463.5M
- CMRX 797.3M
- IPO Year
- XPER 2003
- CMRX 2013
- Fundamental
- Price
- XPER $7.74
- CMRX $8.50
- Analyst Decision
- XPER Strong Buy
- CMRX Hold
- Analyst Count
- XPER 3
- CMRX 4
- Target Price
- XPER $19.00
- CMRX $8.51
- AVG Volume (30 Days)
- XPER 322.6K
- CMRX 8.4M
- Earning Date
- XPER 05-07-2025
- CMRX 03-21-2025
- Dividend Yield
- XPER N/A
- CMRX N/A
- EPS Growth
- XPER N/A
- CMRX N/A
- EPS
- XPER N/A
- CMRX N/A
- Revenue
- XPER $493,688,000.00
- CMRX $212,000.00
- Revenue This Year
- XPER $0.74
- CMRX $2,685.38
- Revenue Next Year
- XPER $8.45
- CMRX $1,050.23
- P/E Ratio
- XPER N/A
- CMRX N/A
- Revenue Growth
- XPER N/A
- CMRX N/A
- 52 Week Low
- XPER $6.89
- CMRX $0.75
- 52 Week High
- XPER $11.49
- CMRX $8.53
- Technical
- Relative Strength Index (RSI)
- XPER 38.91
- CMRX 83.05
- Support Level
- XPER $8.00
- CMRX $8.41
- Resistance Level
- XPER $8.24
- CMRX $8.52
- Average True Range (ATR)
- XPER 0.24
- CMRX 0.02
- MACD
- XPER 0.02
- CMRX -0.15
- Stochastic Oscillator
- XPER 20.55
- CMRX 62.50
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.